文献速递临床试验与 GCP流行病学与生物统计

新欧洲临床试验法规的经验与挑战

Experiences and challenges with the new European Clinical Trials Regulation.
PubMed 文献 · Trials · 2024-01-02

本文基于三项欧洲多国暴发易发传染病临床研究,描述新欧洲临床试验法规下CTIS系统的审批时间、申请文件规模和信息请求数量,并探讨各研究在监管框架内的实际体验。结果显示监管与伦理审批时间虽有改善但仍过慢,且存在申请要求冲突、文件负担增加、重要修改提交障碍和技术障碍等问题。

要点

  • 新法规实施后监管与伦理审批时间有所改善,但对暴发情境下的研究仍过慢。
  • 新审批程序存在申请要求冲突、文件负担增加、重要修改提交障碍和技术障碍。
  • CTIS承诺降低行政门槛但未实现,系统限制与延误对所有临床研究不利。

核心结论

  • CTIS承诺降低行政门槛但未实现,需紧急应对挑战以便国际研究合作者未来有效管理卫生危机。
  • 系统施加的限制与延误对所有临床研究不利,尤其是公共资助的学术研究。

研究设计与样本

  • 基于三项欧洲多国暴发易发传染病临床研究(Bari-SolidAct、AXL-SolidAct、MOSAIC)的经验,报告每项研究的审批时间、申请文件规模和信息请求数量,并探讨各研究在监管框架内的体验。

主要发现

  • 自新法规实施以来,监管与伦理审批时间有所改善,但审批时间线仍不可接受地慢,尤其是在不断演变的暴发情境下开展的研究。
  • 新监管审批程序内存在申请要求冲突、文件负担增加、重要修改提交障碍和削弱性的技术障碍的证据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The new European Medicines Agency (EMA) Clinical Trials Information System (CTIS), based on the Clinical Trials Regulation (CTR EU 536/2014), came into full effect on 31 January 2022 and was intended to provide an easier, more streamlined approach to the registration of clinical trials taking place in Europe. Using the experience gained on the new regulatory framework from three multi-national European clinical research studies of outbreak-prone infectious diseases, this article describes the advantages and shortcomings of the new clinical trial submission procedure. METHODS: We report the time to approval, size of the application dossier, and number of requests for information (RFIs) for each study. We also explore the experience of each study within the regulatory framework and its use of CTIS to document the real-world, practical consequences of the system on individual studies. The study assesses the experience of three multi-country studies conducted in Europe working within the EU and non-EU regulatory environments. RESULTS: While the time to regulatory and ethical approval has improved since the implementation of the new regulation, the timelines for approvals are still unacceptably slow, particularly for studies being conducted in the context of an evolving outbreak. Within the new regulatory approval procedure, there is evidence of conflicting application requirements, increased document burden, barriers to submitting important modifications, and debilitating technical hurdles. CONCLUSIONS: CTIS promised to lower the administrative bar, but unfortunately this has not been achieved. There are challenges that need to be urgently confronted and addressed for international research collaborators to effectively manage health crises in the future. While the value of multi-national outbreak research is clear, the limitations and delays imposed by the system, which raise challenging ethical questions about the regulation, are prejudicial to all clinical research, especially publicly funded academic studies. This report is relevant to both regulators and clinical researchers. It is hoped that these findings can help improve pan-European clinical trials, especially for the purpose of epidemic preparedness and response. TRIAL REGISTRATION: This paper references experiences gained during management of three pan-European trials: EU-SolidAct's Bari-SolidAct (CT No. 2022-500385-99-00 - 15 March 2022) and AXL-SolidAct (CT No. 2022-500363-12-00 - 19 April 2022), and MOSAIC (CT No. 2022-501132-42-00 - 22 June 2022).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Patrick-Brown TDJH, Bourner J, Kali S, et al. Experiences and challenges with the new European Clinical Trials Regulation. Trials. 2024. PMID: 38167484. doi:10.1186/s13063-023-07869-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。